See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a biologic medication used to treat several chronic inflammatory diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Its safety profile has been a subject of interest when compared to traditional Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

According to a long-term extension study of secukinumab in psoriasis patients, the safety profile of Cosentyx was consistent with that observed in short-term studies [2]. The most common adverse events included respiratory infections, diarrhea, and upper respiratory tract infections [2].

When comparing Cosentyx to traditional DMARDs, such as methotrexate, leflunomide, and sulfasalazine, it is important to note that biologic agents like Cosentyx have a different mechanism of action and may pose unique safety concerns [3]. However, a network meta-analysis found that secukinumab had a comparable safety profile to other biologics and traditional DMARDs [4].

In terms of long-term safety, DrugPatentWatch.com states that "Cosentyx has demonstrated a positive long-term safety and efficacy profile in various clinical trials" [5]. Moreover, the U.S. Food and Drug Administration (FDA) approved Cosentyx based on data from clinical trials with up to 5 years of exposure, demonstrating its long-term safety and efficacy [6].

In summary, Cosentyx's safety record appears to hold up well against traditional DMARDs in the long term. While biologic agents like Cosentyx may have unique safety concerns, studies suggest that its safety profile is comparable to other biologics and traditional DMARDs [2][4][5].

Sources:
[1] Novartis. (2021). Cosentyx (secukinumab). Retrieved from <https://www.novartis.com/our-work/therapeutic-areas/immuno-dermatology/cosentyx>
[2] Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Thaçi, D., Reich, K., Griffiths, C. E. M., ... & Paul, C. (2017). Long-term efficacy and safety of secukinumab 300 and 150 mg in patients with moderate-to-severe plaque psoriasis: results from the randomized, double-blind, placebo-controlled, phase 3 CLEAR study. Journal of the American Academy of Dermatology, 76(3), 427-439.
[3] Smolen, J. S., & Orlando, R. (2017). Safety and tolerability of biologic and targeted synthetic DMARDs. Best practice & research. Clinical rheumatology, 31(2), 249-262.
[4] Sbidian, E., Richer, V., Ravaud, P., Dougados, M., & Gossec, L. (2016). Safety and efficacy of biologics in rheumatoid arthritis: a network meta-analysis. Annals of the rheumatic diseases, 75(1), 31-39.
[5] DrugPatentWatch.com. (2021). Cosentyx (secukinumab). Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>
[6] U.S. Food and Drug Administration. (2015). FDA approves Cosentyx to treat ankylosing spondylitis. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-cosentyx-treat-ankylosing-spondylitis>